Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Bromodomain and extra-terminal domain (BET) as a therapeutic target in a mouse model of secondary hemophagocytic lymphohistiocytosis (HLH)

View Full Paper
Ask AI
Bookmark
Share

Authors

PMPaola Martina MarraPRPunithavathi Ranganathan

Discussion

Loading...

Member takes

Overview

Inhibition of BET proteins reduced splenomegaly and cytokine storm in a murine model of secondary hemophagocytic lymphohistiocytosis, suggesting therapeutic potential.

Key Points

  • Treatment with OPN-51107 alleviated inflammation and organomegaly in HLH mice, improving overall health.
  • Significant reduction in splenomegaly (p<0.0001) and improvement in red blood cell counts (p=0.0035) was observed in treated mice.
  • Analyzing immune populations revealed a restoration of CD11b+ and CD4+ cells with BET inhibition, compared to vehicle-treated cohorts.
  • Targeting BET proteins in HLH may provide a new avenue for therapeutic strategies against this severe inflammatory syndrome.

Cite This Study

Marra et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236d9fahttps://doi.org/10.1182/blood-2025-2987
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract B012: Bromodomain and extra-terminal domain (BET) as a therapeutic target in a mouse model of secondary hemophagocytic lymphohistiocytosis (HLH)2025
  2. 2BET inhibition targets pathogenic interstitial macrophages to limit antibody mediated fibrosis in bronchiolitis obliterans chronic gvhd2025
  3. 3Tamoxifen-inducible Pld3 Pld4 knockout mouse model as an animal model for secondary HLH and its treatment 20272025
  4. 4A novel spontaneous HLH mouse model by engrafting human HSCs into b-ndg MGMT3 mice2025
  5. 5Efficacy and mechanism of BTK degrader nx-5948 in secondary hemophagocytic lymphohistiocytosis2025